Table 2.
Adverse Effect | Reference | Benefits | Reference |
---|---|---|---|
Gastric cancer | Kim et al. [47] Ward et al. [48] Keszei et al. [49] Xie et al. [83] Song et al. [57] Zheng et al. [62] |
Adult glioma | Dubrow et al. [53]; Xie et al. [83] |
Colorectal cancer | De Roos et al. [54]; Cross et al. [55]; DellaValle [51]; Cantwell et al. [84] Xie et al. [83]; Van Hecke et al. [60] Bestide et al. [61] |
Reduction of blood pressure | Kapil et al. [65]; Berry et al. [66]; Ashworth et al. [67]; Amaral et al. [69]; Ling et al. [70]; Sievro et al. [71] |
Esophageal cancer | Cross et al. [55]; Keszei et al. [49]; Xie et al. [83] |
Atherosclerosis prevention | Bondonno et al. [78]; Burnley-Hall et al. [79] |
Thyroid cancer | Ward et al. [48]; Aschebrook-Kilfoy et al. [59]; Xie et al. [83]; Bahadoran et al. [56] |
Protection against ischemia- reperfusion |
Yang et al. [46]; Lefer et al. [80] |
Renal cell carcinoma | Weyer et al. [50]; DellaVale et al. [51]; Grieb [52]; Xie et al. [83]; Hu et al. [58] |
Exercise capacity | Coggan et al. [81] Coggan et al. [82] |
Methemoglobinemia | Chan et al. [63] | Stroke prevention | Bondonno et al. [78]; Burnley-Hall et al. [79] |
Hypothyroidism | Ward et al. [48]; Xie et al. [83] |
Insulin resistance, glucose tolerance | Ghasemi, Ghebi [72]; Khalifi et al. [73]; Gilchrist et al. [74]; Cermak et al. [75] |
Breast cancer | Yang et al. [46]; Xie et al. [83] |
Reduction of triglycerides | Zand et al. [76] |
Nitrosative stress | D’Ischia et al. [37] |